Ascenion’s portfolio company has dosed the first patient with its lead candidate TK-8001, a new therapy to target MAGE-A1 positive solid tumours.

With the new round of funding, Aignostics aims to continue growing their team, putting a stronger focus on the US market, and accelerating their investment into their platform and regulatory excellence.

Dermagnostix will use the funds to launch its lead product PsorX in Europe and extend its game-changing approach for the molecular diagnosis of skin diseases to further indications.

Johanna Reimann joined Ascenion in April 2022 as PR & Event Manager. She will support the Munich team in organizing BioVaria and other events and help manage cross-media communications with key stakeholders.

• 29-30 November 2022 in Strasburg, France
• 7-8 December 2022 online
• Applications to the Pitch Sessions until 9 September 2022
   

• EUR 47 million committed by fund initiators Ascenion and Goethe-University together with the European Investment Fund (EIF), Evotec, and other investors
• Focus on high-potential, early-stage life-science start-ups and projects, sourced from Ascenion’s and Innovectis’ partner institutions and other European academic institutions
• 15 + 5 years timeframe enables the partners – and the institutions they represent – to participate in future profits
  
   

TANGO Therapeutics will employ two CRISPR technologies invented by Ulrich Elling at IMBA and in part by Krzysztof Chylinski at VBCF to discover genes involved in tumourigenesis and immune evasion as targets for next-generation therapies.

Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.

16 May 2022, Munich – This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting…

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.

BioVaria will take place in a hybrid format on May 11 and 12, 2022 - live at the Sofitel in Munich and virtually. 14 technology transfer partners from five European countries will present more than 50 commercially attractive licensing opportunities. Application for the Startup Pitch & Partner programme is now open until March 1, 2022.

Céline Christiansen has joined the Berlin team as technology scout. She will closely work with MDC and Charité scientists, supporting them in all IP- and transfer-related aspects of their work.

The financing round was supported by a selected network of investors from medical and financial sectors. It enables the start-up to advance its fully automated ‘lab-in-a-box’ system for the molecular diagnosis of skin diseases to the market.

Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.

On 30 November 2021, Ascenion will host the first GO-Bio Information Webinar as part of our BMBF-funded Life Science Digital Hub project. Participants…